BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36099542)

  • 1. Predictive Factors for Magnetic Resonance Imaging Changes Suggestive of Demyelination in Adult Patients with Uveitis Scanned Prior to Commencing Adalimumab Therapy.
    Sanghi P; Luis J; Ajamil S; Yeung IY; Hindle E; Sandhu S; Hassan S; Turner B; Rees A; Westcott M
    Ocul Immunol Inflamm; 2023 Nov; 31(9):1804-1812. PubMed ID: 36099542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report.
    Rojas-Carabali W; Boada-Robayo L; Chacón-Zambrano D; Criollo Porras E; Kerguelén Dumar V; de-la-Torre A
    Ocul Immunol Inflamm; 2023 Nov; 31(9):1873-1876. PubMed ID: 36150118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.
    Kouwenberg CV; Koopman-Kalinina Ayuso V; de Boer JH
    Acta Ophthalmol; 2022 Jun; 100(4):e994-e1001. PubMed ID: 34532967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 5. The effectiveness of adalimumab treatment for non-infectious uveitis.
    Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Immunol Med; 2019 Jun; 42(2):79-83. PubMed ID: 31315546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
    Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ophthalmic use of TNFα inhibitor: adalimumab treatment in uveitis].
    Géhl Z; Szepessy Z; Nagy ZZ
    Orv Hetil; 2021 Aug; 162(34):1370-1375. PubMed ID: 34428173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.
    Murray GM; Griffith N; Sinnappurajar P; Al Julandani DA; Clarke SLN; Hawley DP; Choi J; Guly CM; Ramanan AV
    Ocul Immunol Inflamm; 2024 May; 32(4):442-446. PubMed ID: 36803373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
    Squires H; Poku E; Bermejo I; Cooper K; Stevens J; Hamilton J; Wong R; Denniston A; Pearce I; Quhill F
    Health Technol Assess; 2017 Nov; 21(68):1-170. PubMed ID: 29183563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.
    Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J
    J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies.
    Hiyama T; Harada Y; Kiuchi Y
    Ocul Immunol Inflamm; 2022 May; 30(4):951-958. PubMed ID: 33560160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature.
    Mahil SK; Andrews TC; Brierley C; Barker JN; Smith CH
    J Dermatolog Treat; 2013 Feb; 24(1):38-49. PubMed ID: 22268700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review.
    Barešić M; Reihl Crnogaj M; Zadro I; Anić B
    Rheumatol Int; 2021 Dec; 41(12):2233-2239. PubMed ID: 34557936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor necrosis factor-alpha therapy for refractory uveitic optic disk neovascularization in active non-infectious posterior and panuveitis.
    Amer R; Cohen O
    Int Ophthalmol; 2021 Oct; 41(10):3523-3531. PubMed ID: 34165681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.
    Atan D; Heissigerova J; Kuffová L; Hogan A; Kilmartin DJ; Forrester JV; Bidwell JL; Dick AD; Churchill AJ
    Mol Vis; 2013; 19():184-95. PubMed ID: 23378732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center.
    Fotiadou C; Lazaridou E; Kemanetzi C; Kyrmanidou E; Ioannides D
    Int J Dermatol; 2015 Sep; 54(9):1105-8. PubMed ID: 25557117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optic neuritis associated with adalimumab in the treatment of uveitis.
    Li SY; Birnbaum AD; Goldstein DA
    Ocul Immunol Inflamm; 2010 Dec; 18(6):475-81. PubMed ID: 20809867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis.
    Ashkenazy N; Saboo US; Abraham A; Ronconi C; Cao JH
    J AAPOS; 2019 Jun; 23(3):151.e1-151.e5. PubMed ID: 31063811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.